Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GH002 (Mebufotenin) in Healthy Volunteers
NCT05753956Phase 1Completed
- Sponsor
- GH Research PLC
- Start
- Dec 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mebufotenin in major depressive disorder (MDD) (8 cohorts), sponsored by GH Research PLC. Primary endpoints: Treatment Emergent Adverse Events up to 7 days, Local Tolerance and 7 more. Started Dec 2022; status: completed.
02
Drugs
mebufotenin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05753956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753956.